Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Source:http://linkedlifedata.com/resource/pubmed/id/18591543

J. Clin. Oncol. 2008 Oct 20 26 30 4934-9

Download in:

View as

General Info

PMID
18591543